Skip to main content
. Author manuscript; available in PMC: 2017 Mar 2.
Published in final edited form as: J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):390–398. doi: 10.1097/QAI.0000000000001274

Figure 2. Cumulative hazards for mortality (A) and for loss to follow-up (B) by time to ART initiation.

Figure 2

ART: Antiretroviral therapy. d: Days . LTFU: Loss to follow-up. mo: Month.